Format

Send to

Choose Destination
Ther Adv Neurol Disord. 2016 Nov;9(6):483-490. Epub 2016 Aug 8.

An update on the evidence base for peginterferon β1a in the treatment of relapsing-remitting multiple sclerosis.

Author information

1
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
2
Johns Hopkins Hospital, 600 North Wolfe Street, Pathology 627, Baltimore, MD 21287, USA.

Abstract

Peginterferon β1a is a modified form of interferon β1a with a polyethylene glycol (PEG) group attached to the α-amino group of the N terminus of the interferon molecule. This modification alters the pharmacokinetic and pharmacodynamic properties of interferon β1a, enabling reduced frequency of dosing and may also result in reduced immunogenicity of the interferon β1a molecule. The efficacy of peginterferon β1a 125 µg administered subcutaneously every 2 or 4 weeks was demonstrated at the end of the placebo-controlled period in the phase III ADVANCE study; both dosing regimens met their primary endpoint of reducing annualized relapse rate (ARR) compared with placebo. Peginterferon β1a administered every 2 weeks resulted in a more robust treatment effect on ARR, sustained disability progression and magnetic resonance imaging endpoints (new or enlarging T2 lesions and gadolinium-enhanced lesions) than peginterferon β1a every 4 weeks. Further reductions in the ARR with additional positive impact on magnetic resonance imaging outcomes were noted in year 2 of the ADVANCE study with the every 2-week dosing regimen. An adverse-effect profile similar to other interferon β formulations coupled with the advantage of a significant reduction in the number of injections, could lead to improved long-term adherence to peginterferon β1a. We review the evidence base for the role of peginterferon β1a in the treatment of relapsing-remitting multiple sclerosis.

KEYWORDS:

multiple sclerosis; peginterferon β1a; randomized clinical trial; relapsing–remitting

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: P. Bhargava receives funding from the National Multiple Sclerosis Society through an Institutional Clinician Training Award. S.D. Newsome has participated in scientific advisory boards for Biogen, Genzyme, and Novartis, and has received research support (paid directly to the institution) from Biogen, Novartis, and the National Multiple Sclerosis Society.

Publication type

Publication type

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center